Introduction. There is inconclusive evidence from randomized controlled trials (RCTs) to support any specific criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy. Our objective was to analyze the criteria for dose adjustment of pharmacologic treatment for diabetes mellitus (DM) in pregnancy. Material and methods. Data sources: MEDLINE, OVID and Cochrane Library were searched from their inception to September 2017. Selection criteria included all trials of DM in pregnancy managed by oral hypoglycemic agents or insulin reporting criteria for pharmacologic therapy dose adjustment. RCTs in women with pregestational DM and gestational DM (GDM) were included. For each trial, data regarding glucose values used for pharmacologic therapy dose adjustment were extracted and carefully reviewed. Results. Of 51 RCTs on therapy for GDM or pregestational DM, 17 (4230 women) were included as they reported criteria for pharmacologic therapy dose adjustment. Most of them (88%, 15/17) included women with GDM only. For RCTs including women with GDM, 12/16 (75%) used the two-step approach, three (19%) the one-step approach and one (6%) either the one-or two-step approach. Regarding the type of initial therapy, 13 (77%) RCTs used different types and doses of insulin; nine (53%) used metformin; five (30%) used glyburide; and one (6%) used placebo. In most RCTs, glucose monitoring was assessed four times daily, i.e. fasting (all RCTs) and two hours (15 RCTs, 88%) after each of the three main meals -breakfast, lunch, and dinner. For fasting glucose target, all used a value <105 mg/dL; nine (53%) used 95 mg/dL as target. Of the 15 RCTs using a two-hour postprandial value as target, 11 (73%) had 120 mg/dL as cutoff. Regarding the criteria for pharmacologic therapy dose adjustment, we found six different criteria. The majority of RCTs (9/17, 53%) used either one or two values per week higher than the target values, of which two-thirds used only one value (35% of total), and one-third (18% of total) two values. Five RCTs (29%) used >50%, one (6%) >30%, and one (6%) >20% of the values higher than the target value; one (6%) used the appearance of glycosuria. Conclusions. When evaluating RCTs which included criteria for pharmacologic GDM therapy dose adjustment, the most common criterion for diagnosis was the two-step test, and the most common used therapies were insulin and metformin. Regarding glucose monitoring, the most common frequency was four times per day, fasting and two hours after each
Introduction. There is inconclusive evidence from randomized controlled trials (RCTs) to support any specific criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy. Our objective was to analyze the criteria for dose adjustment of pharmacologic treatment for diabetes mellitus (DM) in pregnancy. Material and methods. Data sources: MEDLINE, OVID and Cochrane Library were searched from their inception to September 2017. Selection criteria included all trials of DM in pregnancy managed by oral hypoglycemic agents or insulin reporting criteria for pharmacologic therapy dose adjustment. RCTs in women with pregestational DM and gestational DM (GDM) were included. For each trial, data regarding glucose values used for pharmacologic therapy dose adjustment were extracted and carefully reviewed. Results. Of 51 RCTs on therapy for GDM or pregestational DM, 17 (4230 women) were included as they reported criteria for pharmacologic therapy dose adjustment. Most of them (88%, 15/17) included women with GDM only. For RCTs including women with GDM, 12/16 (75%) used the two-step approach, three (19%) the one-step approach and one (6%) either the one-or two-step approach. Regarding the type of initial therapy, 13 (77%) RCTs used different types and doses of insulin; nine (53%) used metformin; five (30%) used glyburide; and one (6%) used placebo. In most RCTs, glucose monitoring was assessed four times daily, i.e. fasting (all RCTs) and two hours (15 RCTs, 88%) after each of the three main meals -breakfast, lunch, and dinner. For fasting glucose target, all used a value <105 mg/dL; nine (53%) used 95 mg/dL as target. Of the 15 RCTs using a two-hour postprandial value as target, 11 (73%) had 120 mg/dL as cutoff. Regarding the criteria for pharmacologic therapy dose adjustment, we found six different criteria. The majority of RCTs (9/17, 53%) used either one or two values per week higher than the target values, of which two-thirds used only one value (35% of total), and one-third (18% of total) two values. Five RCTs (29%) used >50%, one (6%) >30%, and one (6%) >20% of the values higher than the target value; one (6%) used the appearance of glycosuria. Conclusions. When evaluating RCTs which included criteria for pharmacologic GDM therapy dose adjustment, the most common criterion for diagnosis was the two-step test, and the most common used therapies were insulin and metformin. Regarding glucose monitoring, the most common frequency was four times per day, fasting and two hours after each main meal, using as target glucose values 95 and 120 mg/dL, respectively.
Introduction
Carbohydrate disorders in pregnancy, including gestational diabetes mellitus (GMD) and pregestational diabetes mellitus (DM), are the most common morbidities complicating pregnancy, with short-and long-term consequences to mothers, fetuses, and newborns. It has been estimated that up to 6-7% or more of all pregnancies are complicated by DM in pregnancy . The latest reports from the International Diabetes Federation estimate that, worldwide, approximately one in seven births in 2015 were complicated by some form of hyperglycemia during pregnancy (53) .
Management for women with carbohydrate disorders in pregnancy includes diet, physical activity, oral hypoglycemic agents or insulin as needed. The management of those women aims to achieve the best possible glycemic control, with normal or near normal glucose values while avoiding hypoglycemia. This management is effective in reducing maternal and neonatal morbidity and mortality (3, 9, 24, 31, 38) .
Nevertheless, the optimal schedule, frequency and timing of glucose monitoring remains disputable, as are the glycemic metabolic goals. Moreover, there is no evidence from randomized controlled trials (RCTs) to support any specific criteria for pharmacologic therapy dose adjustment.
Thus, the aim of this review was to analyze the criteria for dose adjustment of pharmacologic treatment for DM in pregnancy through a systematic review of RCTs.
Material and methods

Search strategy
This review was performed according to a protocol recommended for systematic review (54) . The review protocol was designed a priori to define methods for collecting, extracting, and analyzing data. The research was conducted with the use of MEDLINE, OVID, and Cochrane Library as electronic databases. The trials were identified with the use of a combination of the following text words: "gestational diabetes", "GDM", "diabetes in pregnancy", "therapy", "treatment", "insulin", "oral hypoglycemic", "metformin", "trial" and "randomized" from the inception of each database to September 2017. Review of articles also included the abstracts of all references that were retrieved from the search. No restrictions on language or geographic location were applied. In addition, the reference lists of all identified articles were examined to identify studies not captured by electronic searches. The electronic search and the eligibility of the studies were independently assessed by two authors (C.C., G.S.). Differences were discussed with a third reviewer (V.B.).
Study selection
Selection criteria included all RCTs of diabetes in pregnancy managed by oral hypoglycemic agents or insulin. Trials in women with pregestational DM and trials in women with GDM were included. Trials in women treated only with exercise or diet at the time of randomization were excluded. Trials in women with impaired glucose tolerance and trials not reporting criteria for dose adjustment of pharmacologic treatment were also excluded. We analyzed retrospective and prospective studies.
Data extraction and risk of bias assessment
The risk of bias in each included study was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. Seven domains related to risk of bias were assessed in each included trial since there is evidence that these issues are associated with biased estimates of treatment effect: (i) random sequence generation; (ii) allocation concealment; (iii) blinding of participants and personnel; (iv) blinding of outcome assessment; (v) incomplete outcome data; (vi) selective reporting; and (vii) other bias. Review authors' judgments were categorized as "low risk", "high risk" or "unclear risk" of bias (54) .
Outcomes and data extraction
For each trial, data regarding glucose values used for pharmacologic therapy dose modification were extracted and carefully reviewed. We also planned to review the type of screening, type of initial therapy (for example insulin vs. oral hypoglycemic agent), frequency of glucose monitoring, and target glucose values. The types of DM screening were defined as one step, i.e. 75 g two-hour glucose load, and two-step, i.e. 50 g one-hour glucose load, followed if abnormal by a 100 g three-hour glucose load test.
The primary outcome was the incidence of macrosomia, as defined by the original trials (13 RCTs defined macrosomia as a birthweight >4000 g, the other four RCTs used a birthweight >90th percentile).
The secondary outcomes were cesarean delivery, maternal hypoglycemia and neonatal hypoglycemia. Primary and secondary outcomes were assessed for each criteria used by the original trials, for example one or two values higher than the target values, a cutoff based on percentage of abnormal glucose values, ultrasound criteria, or symptoms.
Primary and secondary outcomes were also assessed in sensitivity analyses according to type of therapy, i.e. oral hypoglycemic agent or insulin.
We also aimed to compare a policy of very tight (i.e. more restrictive) vs. tight (i.e. less restrictive) control for diabetes in pregnancy to assess the best criteria for pharmacologic therapy dose adjustment, using indirect metaanalysis.
We considered a policy of very tight control to use the following criteria:
• one or two values higher than the target values (i.e. intervention group)
We considered a policy of tight control to use the following criteria:
• >50% higher than the target values (i.e. comparison group)
Other criteria (for example >20% or >30% higher, ultrasound criteria, symptoms) were not included in the indirect meta-analysis.
Statistical analyses
To show robustness of our review, we aimed to perform a meta-analysis for the primary outcome (i.e. incidence of macrosomia) (54, 55) . To complete such analyses, we performed an adjusted indirect meta-analysis to compare a policy of very tight control with a policy of tight control for diabetes in pregnancy, as previously described (56) . The adjusted indirect comparison meta-analysis was performed according to the most widely applied indirect comparison method by Bucher et al. In this method, the randomization of each trial is maintained, and the direct comparison is used to yield an indirect comparison (55, 56) . In the indirect comparison, meta-analysis, data were combined in a two-stage approach in which outcomes were analyzed in their original study and then summary statistics combined using standard summary data meta-analysis techniques to give an overall measure of effect (55, 56) .
The data analysis of the indirect meta-analysis was completed independently by two authors (C.C., G.S.) using REVIEW MANAGER v. 5.3 (The Nordic Cochrane Center, Cochrane Collaboration, 2014, Copenhagen, Denmark). The completed analyses were then compared, and any difference was resolved by discussion with a third reviewer (V.B.) (54) .
Data from each eligible study were extracted without modification of original data onto custom-made data collection forms. A 2 9 2 table was assessed for relative risk (54) .
Indirect meta-analysis was performed using the random effects model of DerSimonian & Laird (54) to produce summary treatment effects in terms of relative risk with 95% confidence interval (CI).
The meta-analysis was reported following the Preferred Reporting Item for Systematic Reviews and Meta-analyses (PRISMA) statement (57) . Before data extraction, the review was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42016053067).
Results
We identified 51 RCTs on therapy for GDM or pregestational diabetes, and assessed these for eligibility ( Figure 1 ) (1-51). Of them, 34 were excluded, and therefore 17 including 4230 women were included (1) (2) (3) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (16) (17) (18) (19) . Figure 2 shows the risk of bias of the included trials. Most of them had low risk of bias in selection, attrition, and reporting.
No trials compared differing criteria for pharmacologic therapy dose adjustment. Most of them (88%, 15/17) included women with GDM only (1-3,5,7-13,16-19).
Refuerzo et al. (14) included women with type II pregestational diabetes only. Hickman et al. (6) included women with both GDM and type II pregestational diabetes. For RCTs including women with GDM, 12/16 (75%) used the two-step test (2, (5) (6) (7) (8) (9) (10) (11) (12) (13) 18, 19) and three trials the one-step test (1, 3, 16) . Spaulonci et al. (17) used either the one-or two-step approach (17) . Sample size ranged from 21 (14) to 1000 women (3) . Regarding the type of initial therapy, 13 (77%) trials used different types and doses of insulin (NPH, regular short-acting, lispro) (1, 3, (6) (7) (8) (9) (10) (12) (13) (14) (17) (18) (19) , nine (53%) trials tested metformin (1, 5, 6, (10) (11) (12) 14, 16, 17) , five (30%) trials tested glyburide (2, 5, 8, 11, 18) , and one (6%) trial used placebo (2) ( Table 1) . Table 2 shows the management of women included in trials. In most of them (14 RCTs, 82%) glucose monitoring was assessed four times daily, i.e. fasting and either one or two hours after each of the three main meals -breakfast, lunch, and dinner (1) (2) (3) 5, 6, 8, (10) (11) (12) (13) (14) 16, 18, 19) ; two (12%) trials assessed four to seven times daily, i.e. fasting, preprandial before lunch and dinner, one and two hours after each main meal -breakfast, lunch, and dinner (7, 17) . Only one (6%) trial carried out monitoring nine times a day, i.e. fasting and one and two hours after each main meal -breakfast, lunch, and dinner (9) . All 17 RCTs used fasting glucose as a target, and 100% had a value <105 mg/dL; nine (53%) used 95 mg/ dL as target. Of the 15 RCTs using the two-hour postprandial value as target, 11 (73%) had 120 mg/dL as cutoff. Of the four RCTs using a one-hour postprandial value as target, two (50%) had 120 mg/dL as cutoff, and the others used 150 mg/dL ( Table 2) . One RCT also considered the Hb1Ac value (18) .
Regarding the glucose values used for dose modification:
• Nine trials (53%) used one or two values higher than the target values (3,5,7,10-12,16,18,19) (i.e. very tight control group); 6/17 (35%) used one value higher than target values (3, 5, 7, 10, 18, 19) , and 3/17 (18%) used two values higher than target values (11, 12, 16) . Of these nine trials, five (56%) used their criteria over 1 week (5, 10, 12, 16, 19) , two over 2 weeks (3, 11) , one over either one or 2 weeks (7), and one over 3 days (18) .
• Five trials (29%) used >50% of the values higher than the target values (2,6,8,9,14) (i.e. tight control group).
• One trial (6%) used >30% of the values higher than the target values (17).
• One trial (6%) used >20% of the values higher than the target values (1).
• One trial (6%) used appearance of glycosuria (13) . Table 3 shows individual data for the primary and secondary outcomes in the overall analysis. Indirect metaanalysis showed no statistically significant difference in the incidence of macrosomia comparing a very tight with a tight policy (8.3 vs. 7.0%; relative risk 1.20, 95% CI 0.87-1.64). Tables 4 and 5 show primary and secondary outcomes in sensitivity analyses in insulin-and metformin-only trials.
Discussion
This systematic review from 17 RCTs, including 4230 women, evaluated the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy. We failed to find any RCT comparing differing criteria for pharmacologic therapy dose adjustment. The majority of the 17 RCTs included women with GDM (88%); used the two- step test (with 100 g glucose load as second step) for GDM diagnosis (75%); insulin (77%) and metformin (53%) as therapies; monitored glucose values four times per day, i.e. fasting and usually two hours after each main meal -breakfast, lunch and dinner (82%); and used as targets a fasting glucose target of 95 mg/dL (53%) and two hours of 120 mg/dL (65%). As described in a review of the Endocrine Society from 2013, a fasting glucose target of <90 mg/dL is associated with a lower risk of macrosomia and other outcomes in women with gestational diabetes, whereas this is unclear in pregestational diabetes (58) . Moreover, therapy adjustment based on the results of postprandial, rather than preprandial, blood glucose values in women with GDM improves glycemic control and decreases the risk of neonatal hypoglycemia, macrosomia, and cesarean delivery (59) .
Regarding our main aim, i.e. evaluating criteria for pharmacologic DM therapy dose adjustment, we found six different criteria. The majority of RCTs (53%) used either one or two values per week higher than the target values, of which two-thirds used only one value (35% of total), and one-third (18% of total) two values.
There are at least 11 variables regarding management of GDM which could affect the outcomes, macrosomia etc. These include: Metformin: increased 500 mg weekly to a maximum of 2500 mg/day allowing a total of 2-3 weeks; after that, insulin was added or women were switched over completely to insulin
Glyburide: increased once a week, maximum total dose of 15 mg/day in 2-3 weeks; after that, insulin was added or women were switched over completely to insulin Refuerzo, 2015 (14) 4 times daily (Table 3) , it is impossible to really assess this comparison given the other 10 variables listed above, which could not be controlled for.
Strengths of the study include the use of the most rigorous methodology for an indirect meta-analysis of RCTs. We are not aware of any other meta-analysis evaluating a policy of very tight vs. tight glycemic control to assess the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy. The variables which may affect pregnancy outcomes in GDM management were carefully reviewed. The most common management strategies for GDM used in RCTs were identified.
There are several limitations in our study. Four RCTs used a different definition of macrosomia. No trials comparing a policy of very tight vs. tight glycemic control to assess the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy could be identified. Therefore, a standard meta-analysis was not feasible. An indirect meta-analysis has wide statistically inconsistency compared with standard meta-analysis. In addition, the risk of overestimation could be high when the indirect comparison of interest relies on only a few trials. The clinical heterogeneity within the trials was very high. Trials included used different protocol management, different diagnostic tests, different sample size, different initial therapy, different glucose monitoring, different target glucose values. Moreover, not all RCTs considered the same outcomes.
Finally, the majority of included RCTs considered neutral protamine Hagedorn (NPH) and regular insulin to be the only options. Nowadays, the use of insulin analogues, in particular the rapid-acting bolus analogues aspart and lispro, achieve postprandial targets with less hypoglycemia compared with regular insulin, with similar fetal outcomes, and.the long-acting insulin analogues glargine and detemir appear safe with similar maternal/fetal outcomes compared with NPH (62) . We included only trials of diabetes in pregnancy managed by oral hypoglycemic agents or insulin. Trials in women treated only with exercise or diet at the time of randomization were excluded. Exercise in pregnancy has been shown to reduce the risk of diabetes in both normal-weight and overweight and obese women (63) (64) (65) (66) , as well as to improve pregnancy outcome in those with GDM (67). When evaluating RCTs which included criteria for pharmacologic GDM therapy dose adjustment, the most common criteria for GDM diagnosis was the two-step test, and the most common therapies used were insulin and metformin. Regarding glucose monitoring, the most common frequency was four times per day, i.e. fasting and after each main meal, using a fasting level of 95 mg/ dL and a two-hour level of 120 mg/dL as targets. Importantly, we found six different criteria for pharmacologic GDM therapy dose adjustment, with the majority using very tight criteria of either one or two values per week higher than the target values, of which two-thirds used only one value (35% of total), and one-third (18% of total) two values. While very tight (one or two abnormal target vales) vs. tight criteria for pharmacologic therapy dose adjustment did not seem to affect outcomes (Table 3) , it is impossible to really assess this comparison given no head-to-head RCTs with this study design. Future well-designed, properly powered RCTs are needed to answer this important clinical question.
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